Barr anticipates generic warfarin approval by early second quarter, firm says.
Executive Summary
BARR IS EXPECTING GENERIC WARFARIN APPROVAL IN FIRST QUARTER "or shortly thereafter," Barr CEO Bruce Downey told an American Stock Exchange Health Care Conference in New York City Jan. 23. To produce a generic, Downey said, Barr has had to overcome "the unavailability of raw material" and "a fierce campaign among pharmacists implying that the generic substitute for the product might not be safe and effective." Barr maintains that its warfarin "is both safe and effective and deserves immediate approval." Barr must also overcome a citizen's petition filed with FDA by Coumadin (warfarin) manufacturer DuPont Merck requesting more stringent bioequivalence standards for generic versions of the anticoagulant drug ("The Pink Sheet" Oct. 14, 1996, T&G-16).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth